Caterina Sposetti

Dana-Farber Cancer Institute

United States

Research Interests

Explore related searches

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (11)

Collaborators (6)

Laura Mazzeo

National Institute of Oncology

Gabriele Martelli

Fondazione IRCCS Istituto Nazionale dei Tumori

siranoush manoukian

Fondazione IRCCS Istituto Nazionale dei Tumori

Chiara Corti

Harvard University

UNITED STATES

Giovanni Fucà

Fondazione IRCCS Istituto Nazionale dei Tumori

Antonia Martinetti

Fondazione IRCCS Istituto Nazionale dei Tumori

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Caterina Sposetti

Research Interests

Explore related searches

Contact this professor

Articles (11)

Collaborators (6)

Laura Mazzeo

Gabriele Martelli

siranoush manoukian

Chiara Corti

Giovanni Fucà

Antonia Martinetti

Make your next move.

Caterina Sposetti

Research Interests

Explore related searches

Contact this professor

Articles (11)

Decoding KRAS mutation in non-small cell lung cancer patients receiving immunotherapy: A retrospective institutional comparison and literature review

Adding fasting-mimicking diet to first-line carboplatin-based chemotherapy is associated with better overall survival in advanced triple-negative breast cancer patients: A subanalysis of the NCT03340935 trial

Real-World Outcomes of Trastuzumab Deruxtecan in Patients With HER2+Metastatic Breast Cancer: The DE-REAL Study

Adding fasting-mimicking diet to first-line carboplatin-based chemotherapy is associated with better overall survival in advanced triple-negative breast cancer patients: A subanalysis of the NCT03340935 trial.

Breast cancers arising in subjects with germline BRCA1 or BRCA2 mutations: different biological and clinical entities with potentially diverse therapeutic opportunities.

Breast cancers arising in subjects with germline<i> BRCA1</i> or<i> BRCA2</i> mutations: Different biological and clinical entities with potentially diverse therapeutic opportunities

HER2-Low Status is Associated with Worse Clinical Outcomes in Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer Patients Treated With First-Line Cyclin-Dependent Kinase 4/6 Inhibitors Plus Endocrine Therapy

Peripheral blood lymphocytes predict clinical outcomes in hormone receptor-positive HER2-negative advanced breast cancer patients treated with CDK4/6 inhibitors

Platinum-based chemotherapy and PARP inhibitors for patients with a germline<i> BRCA</i> pathogenic variant and advanced breast cancer (LATER-BC): retrospective multicentric analysis of post-progression treatments

Platinum-based chemotherapy and PARP inhibitors for patients with a germline BRCA pathogenic variant and advanced breast cancer (LATER-BC): retrospective multicentric analysis of post-progression treatments

Prognostic significance of HER2-low status in HR-positive/HER2-negative advanced breast cancer treated with CDK4/6 inhibitors

Collaborators (6)

Laura Mazzeo

Gabriele Martelli

siranoush manoukian

Chiara Corti

Giovanni Fucà

Antonia Martinetti

Make your next move.